2. Educational Objectives

3. Metastatic Breast Cancer: Scope of the Problem

4. Metastatic Breast Cancer: General Treatment Considerations

6. Therapeutic Goals/Endpoints in MBC

7. MBC: Impact of Chemotherapy

8. Treatment Options for Advanced Breast Cancer

10. First-Line Chemotherapy Options

11. Response Rates with Single-Agent Chemotherapeutic Agents in MBC

12. Highlights of the Evolution of Taxanes in Oncology

13. Taxanes in the Treatment of MBC

14. Conventional Taxanes: Pharmacologic and Pharmacodynamic Differences

15. Conventional Taxanes: Impact of Solvents

16. Albumin Role: Natural Carrier of Hydrophobic Molecules in Humans

17. Increased Intratumoral Concentration With nab-Paclitaxel

18. Differentiating the Taxanes: Toxicity

19. Making Taxanes Less “Tax-ing”

20. Taxane Toxicities

21. Randomized Comparison Between Taxanes

22. Taxanes: Premedication Guidelines

23. Taxane Hypersensitivity Reactions

24. Anemia

25. Differentiating the Taxanes: Efficacy

26. Pivotal Phase III Trials of Paclitaxel Single Agent and Combinations

27. Pivotal Phase III Trials of Docetaxel Single Agent and Combinations

29. TAX 311: Paclitaxel versus Docetaxel in Metastatic Breast Cancer

31. TAX 311: Paclitaxel Versus Docetaxel in Metastatic Breast Cancer – OS

32. TAX 311: Hematologic Toxicity

33. TAX 311: Non-Hematologic Toxicity

34. TAX 311: Quality of Life Analysis

35. Phase III Trial of nab-Paclitaxel vs Paclitaxel in MBC: Design

36. Phase III Trial of nab-Paclitaxel vs Paclitaxel in MBC: Results

37. Phase III Trial of nab-Paclitaxel vs Paclitaxel in MBC: TTP

38. Phase III Trial of nab-Paclitaxel vs Paclitaxel in MBC: OS

39. Phase III Trial of nab-Paclitaxel vs Paclitaxel in MBC: OS ( ≥ 2nd-line Patients)

40. nab-Paclitaxel vs Paclitaxel in MBC: Hematologic Toxicities

41. nab-Paclitaxel vs Paclitaxel in MBC: Non-Hematologic Toxicities

42. nab-Paclitaxel vs Paclitaxel in MBC: Neuropathy Resolution

43. Phase II Study of Weekly nab- Paclitaxel in Taxane-Refractory MBC

44. Taxanes: Cost-effectiveness Model

45. Cost-effectiveness Model: Methodology (cont.)

46. Costs per Cycle

47. Frequency of Grade 3/4 Toxicities (O’Shaughnessy 2003)

48. Treatment Costs per Toxicity for Taxane Therapy

49. Cost-effectiveness Ratios

50. Model Analysis of Total Costs

51. Conclusions